These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9260728)

  • 1. Serotonin, dopamine, and motor effects in Parkinson's disease.
    Miyawaki E; Meah Y; Koller WC
    Clin Neuropharmacol; 1997 Aug; 20(4):300-10. PubMed ID: 9260728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.
    Di Matteo V; Pierucci M; Esposito E; Crescimanno G; Benigno A; Di Giovanni G
    Prog Brain Res; 2008; 172():423-63. PubMed ID: 18772045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies?
    Di Giovanni G; Di Matteo V; Pierucci M; Benigno A; Esposito E
    Curr Med Chem; 2006; 13(25):3069-81. PubMed ID: 17073648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin and Parkinson's disease: On movement, mood, and madness.
    Fox SH; Chuang R; Brotchie JM
    Mov Disord; 2009 Jul; 24(9):1255-66. PubMed ID: 19412960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease.
    Jenner P; Sheehy M; Marsden CD
    Br J Clin Pharmacol; 1983; 15 Suppl 2(Suppl 2):277S-289S. PubMed ID: 6337612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract]   [Full Text] [Related]  

  • 7. Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
    Rascol OJ; Sabatini U; Chollet F; Montastruc JL; Marc-Vergnes JP; Rascol A
    Adv Neurol; 1993; 60():419-21. PubMed ID: 8420165
    [No Abstract]   [Full Text] [Related]  

  • 8. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Adv Neurol; 1996; 69():497-501. PubMed ID: 8615171
    [No Abstract]   [Full Text] [Related]  

  • 9. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.
    Chase TN; Konitsiotis S; Oh JD
    Adv Neurol; 2001; 86():355-60. PubMed ID: 11553996
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials.
    Kalia LV; Brotchie JM; Fox SH
    Mov Disord; 2013 Feb; 28(2):131-44. PubMed ID: 23225267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin and Parkinson's disease.
    Hesselink JM
    Am J Psychiatry; 1993 May; 150(5):843-4. PubMed ID: 8480847
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: implications for human Parkinson's disease.
    Reader TA; Dewar KM
    Neurochem Int; 1999 Jan; 34(1):1-21. PubMed ID: 10100192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insight into the therapeutic role of the serotonergic system in Parkinson's disease.
    Ohno Y; Shimizu S; Tokudome K; Kunisawa N; Sasa M
    Prog Neurobiol; 2015 Nov; 134():104-21. PubMed ID: 26455457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The relevance of dopamine agonists in the treatment of depression].
    Clausius N; Born C; Grunze H
    Neuropsychiatr; 2009; 23(1):15-25. PubMed ID: 19272288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
    Carta M; Carlsson T; Kirik D; Björklund A
    Brain; 2007 Jul; 130(Pt 7):1819-33. PubMed ID: 17452372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depression in Parkinson's disease: a biochemical model.
    Sano M; Stern Y; Cote L; Williams JB; Mayeux R
    J Neuropsychiatry Clin Neurosci; 1990; 2(1):88-92. PubMed ID: 2136066
    [No Abstract]   [Full Text] [Related]  

  • 18. Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss?
    Peppe A; Stanzione P; Pierantozzi M; Semprini R; Bassi A; Santilli AM; Formisano R; Piccolino M; Bernardi G
    Electroencephalogr Clin Neurophysiol; 1998 Apr; 106(4):374-82. PubMed ID: 9741766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The serotonergic system in Parkinson's disease.
    Huot P; Fox SH; Brotchie JM
    Prog Neurobiol; 2011 Oct; 95(2):163-212. PubMed ID: 21878363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid hypofunction in Parkinson's disease.
    Sandyk R; Gillman MA
    Med Hypotheses; 1985 Feb; 16(2):179-82. PubMed ID: 2581117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.